PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder
NCT ID: NCT04353921
Last Updated: 2022-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
24 participants
OBSERVATIONAL
2020-06-30
2022-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Psilocybin for Major Depressive Disorder (MDD)
NCT03866174
Effects of Psilocybin in Major Depressive Disorder
NCT03181529
Psilocybin for Major Depressive Disorder
NCT05675800
Psilocybin for Major Depressive Disorder (MDD)
NCT06308653
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
NCT04670081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single-Dose of Psilocybin
No intervention will be administered as part of this study.
No intervention will be administered as part of this study.
Niacin-Control
No intervention will be administered as part of this study.
No intervention will be administered as part of this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention will be administered as part of this study.
No intervention will be administered as part of this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Usona Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Segal Trials
Lauderhill, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PSIL201-LTFU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.